Targeting NK cells for anti-cancer immunotherapy: clinical and pre-clinical approaches
The recent success of checkpoint blockade has highlighted the potential of immunotherapy approaches for cancer treatment. While the majority of approved immunotherapy drugs target T cell subsets, it is appreciated that other components of the immune system have important roles in tumor immune-survei...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2016-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fimmu.2016.00152/full |
| _version_ | 1811197740225396736 |
|---|---|
| author | Sebastian eCarotta Sebastian eCarotta |
| author_facet | Sebastian eCarotta Sebastian eCarotta |
| author_sort | Sebastian eCarotta |
| collection | DOAJ |
| description | The recent success of checkpoint blockade has highlighted the potential of immunotherapy approaches for cancer treatment. While the majority of approved immunotherapy drugs target T cell subsets, it is appreciated that other components of the immune system have important roles in tumor immune-surveillance as well and thus represent promising additional targets for immunotherapy. Natural killer cells are the body’s first line of defense against infected or transformed cells as they kill target cells in an antigen-independent manner. Although several studies have clearly demonstrated the active role of NK cells in cancer-immune surveillance, only few clinically approved therapies currently exist that harness their potential. Our increased understanding of NK cell biology over the past few years has renewed the interest in NK cell based anti-cancer therapies, which has lead to a steady increase of NK cell based clinical and pre-clinical trials. Here, the role of NK cells in cancer immunesurveillance is summarized and several novel approaches to enhance NK cell cytotoxicity against cancer are discussed. |
| first_indexed | 2024-04-12T01:18:25Z |
| format | Article |
| id | doaj.art-21294cf7bf9340259c16758707795326 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-12T01:18:25Z |
| publishDate | 2016-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-21294cf7bf9340259c167587077953262022-12-22T03:53:51ZengFrontiers Media S.A.Frontiers in Immunology1664-32242016-04-01710.3389/fimmu.2016.00152190237Targeting NK cells for anti-cancer immunotherapy: clinical and pre-clinical approachesSebastian eCarotta0Sebastian eCarotta1Boehringer Ingelheim RCV GmbH & Co KGThe Walter & Eliza Hall InstituteThe recent success of checkpoint blockade has highlighted the potential of immunotherapy approaches for cancer treatment. While the majority of approved immunotherapy drugs target T cell subsets, it is appreciated that other components of the immune system have important roles in tumor immune-surveillance as well and thus represent promising additional targets for immunotherapy. Natural killer cells are the body’s first line of defense against infected or transformed cells as they kill target cells in an antigen-independent manner. Although several studies have clearly demonstrated the active role of NK cells in cancer-immune surveillance, only few clinically approved therapies currently exist that harness their potential. Our increased understanding of NK cell biology over the past few years has renewed the interest in NK cell based anti-cancer therapies, which has lead to a steady increase of NK cell based clinical and pre-clinical trials. Here, the role of NK cells in cancer immunesurveillance is summarized and several novel approaches to enhance NK cell cytotoxicity against cancer are discussed.http://journal.frontiersin.org/Journal/10.3389/fimmu.2016.00152/fullImmunotherapyCancerNK cellsNatural Killer cellsimmune therapyCheckpoint inhibitors |
| spellingShingle | Sebastian eCarotta Sebastian eCarotta Targeting NK cells for anti-cancer immunotherapy: clinical and pre-clinical approaches Frontiers in Immunology Immunotherapy Cancer NK cells Natural Killer cells immune therapy Checkpoint inhibitors |
| title | Targeting NK cells for anti-cancer immunotherapy: clinical and pre-clinical approaches |
| title_full | Targeting NK cells for anti-cancer immunotherapy: clinical and pre-clinical approaches |
| title_fullStr | Targeting NK cells for anti-cancer immunotherapy: clinical and pre-clinical approaches |
| title_full_unstemmed | Targeting NK cells for anti-cancer immunotherapy: clinical and pre-clinical approaches |
| title_short | Targeting NK cells for anti-cancer immunotherapy: clinical and pre-clinical approaches |
| title_sort | targeting nk cells for anti cancer immunotherapy clinical and pre clinical approaches |
| topic | Immunotherapy Cancer NK cells Natural Killer cells immune therapy Checkpoint inhibitors |
| url | http://journal.frontiersin.org/Journal/10.3389/fimmu.2016.00152/full |
| work_keys_str_mv | AT sebastianecarotta targetingnkcellsforanticancerimmunotherapyclinicalandpreclinicalapproaches AT sebastianecarotta targetingnkcellsforanticancerimmunotherapyclinicalandpreclinicalapproaches |